Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells
dc.contributor.author | Karabulut, B | |
dc.contributor.author | Erten, C | |
dc.contributor.author | Gul, MK | |
dc.contributor.author | Cengiz, E | |
dc.contributor.author | Karaca, B | |
dc.contributor.author | Kucukzeybek, Y | |
dc.contributor.author | Gorumlu, G | |
dc.contributor.author | Atmaca, H | |
dc.contributor.author | Uzunoglu, S | |
dc.contributor.author | Sanli, UA | |
dc.contributor.author | Baran, Y | |
dc.contributor.author | Uslu, R | |
dc.date.accessioned | 2024-07-18T12:05:06Z | |
dc.date.available | 2024-07-18T12:05:06Z | |
dc.description.abstract | Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer. (C) 2008 International Federation for Cell Biology. Published by Elsevier Ltd. All rights reserved. | |
dc.identifier.issn | 1065-6995 | |
dc.identifier.other | 1095-8355 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/9541 | |
dc.language.iso | English | |
dc.publisher | WILEY | |
dc.subject | ZOLEDRONIC ACID | |
dc.subject | BISPHOSPHONATES | |
dc.subject | PROGRESSION | |
dc.subject | GROWTH | |
dc.subject | MARKER | |
dc.title | Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells | |
dc.type | Article |